Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects With Moderate or Severe Crohn's Disease
收藏DataCite Commons2025-12-20 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005572/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.
提供机构：
Vivli
创建时间：
2020-04-29
